Testing BHV-1400 for IgA Kidney Disease
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a new drug called BHV-1400 can slow down or help IgA nephropathy, a condition where the immune system damages the kidneys. You'll be monitored to see if the drug is safe and effective for you.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Confirmed diagnosis of IgA nephropathy (IgAN) from a kidney biopsy done within the last 10 years
- Significant protein in your urine (≥0.75 g/g measured over 24 hours or ≥1.0 g per day)
- Kidney function with eGFR ≥30 mL/min/1.73m² (moderately reduced but not near kidney failure)
- Already taking blood pressure medication (ACE inhibitor or ARB) at a stable dose for at least 90 days
- No other kidney disease besides IgAN, and no signs of rapidly worsening kidney function
- Not currently requiring dialysis or a kidney transplant
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine, BHV-1400, for people with IgA Nephropathy, a kidney disease. The goal is to see if it can help slow down kidney damage.
This trial tests a medicine called CM313 in people with IgA nephropathy, a kidney disease. It may help reduce protein in the urine, which is a sign of kidney damage.
This trial looks at how bacteria in the gut (microbiome) and substances in the body (metabonomics) relate to IgA nephropathy, a kidney condition. The goal is to understand patterns that may help explain the disease and improve future care.
This trial tests whether hydroxychloroquine can help slow kidney damage in people with IgA nephropathy. You may qualify if you have this kidney disease, are already on two standard medicines (RAAS inhibitors and SGLT2 inhibitors), and have ongoing protein in your urine.
This trial tests whether a new medicine called finerenone can help people with IgA nephropathy, a kidney disease. You may be able to join if you are already on blood pressure medications, your kidney function is at a certain level, and you haven't needed immune-suppressing drugs recently.
This trial tests an experimental medicine called NM8074 for people with IgA nephropathy, a type of kidney disease. It aims to see if NM8074 can help protect your kidneys and reduce damage.
Hear when a new IgA Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.